Navigation Links
ThromboGenics N.V.: Business Update
Date:11/6/2008

howed that microplasmin-treated patients had a statistically significant improvement in the level of damage to the blood brain barrier compared to placebo-treated patients, measured using the marker of matrix metalloproteinase (MMP). MMP activation plays a crucial role in the pathogenesis of brain edema and hemorrhagic transformation after ischemic stroke.

It remains ThromboGenics' intention that it will only move forward with the development of microplasmin for the treatment of stroke in cooperation with a partner. This view is based on both the risks and cost associated with the development of new stroke therapies, and the Company's desire to invest in its other attractive pipeline product candidates, including microplasmin in the treatment of back of the eye diseases.

Staphylokinase (THR-100)

ThromboGenics partner for the clinical development and commercialization of THR-100, Bharat Biotech, continues to work with the Indian authorities to gain the necessary approvals to begin a Phase III trial with this novel variant of Recombinant Staphylokinase. The initial trial will evaluate THR-100 for the treatment of acute myocardial infarction (AMI), or heart attack. Given the commercial strengths of Bharat in this market and the clinical advantages of THR-100, it is hoped that this novel product will quickly become the market leader for the thrombolytic treatment of heart attacks in India.

TB-403 - Working with Roche on this Potential Breakthrough Cancer Treatment

ThromboGenics, in conjunction with its partner BioInvent, has made good progress in transferring this novel anti-cancer agent to Roche following the strategic alliance signed in June 2008.

Following the successful completion of the initial Phase I study, the parties have begun a Phase Ib trial with TB-403 in end-stage cancer patients. This study, which will recruit approximately 24 patients, is designed to provide both safety data on TB-403 when used in cancer patients
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThromboGenics Announces Half Year Results 2008
2. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
3. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
4. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
5. ThromboGenics N.V. - Business Update
6. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
7. ThromboGenics Announces 2007 Full Year Results
8. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
9. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
10. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
11. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Freeslate, Inc ., the ... that Lupin Limited, one of India’s top five pharmaceutical ... PharmD System for high throughput solid form screening. ... on a wide range of quality, affordable generic and ...
(Date:1/14/2014)... 2014 Date: Friday, April 11, 2014 , ... Club, 1360 Almshouse Road, Warrington, Pa. , Details: ... dedicated to finding a cure for hepatitis B and improving ... its annual Crystal Ball on Friday, April 11 at Warrington ...
(Date:1/14/2014)... provider of strategic communications services to corporations and organizations preparing for ... United States and Europe , today ... to the firm,s Washington, D.C. office. ... years of service as Associate Commissioner for the Office of External ...
(Date:1/14/2014)... , Jan. 14, 2014 The largest ... research medicinal plants and therapeutic derivatives thereof has ... professionals, and researchers about the challenges of adulterated ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society for ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8
... Inc. ("OriGene") today announced it has raised an ... With this financing, OriGene completed the acquisition of ... a manufacturer and provider of monoclonal antibodies (mAb) ... completes the establishment of its technology center to ...
... NKTR ) will announce its financial results ... on Wednesday, February 25, 2009, after the close,of U.S.-based ... will host a conference call to review the results ... (PT). , The press release ...
... VALLEY COTTAGE, N.Y., Feb. 11 XTL,Biopharmaceuticals Ltd. (Nasdaq: ... Mr.,David Grossman and Mr. Boaz Shweiger have been appointed ... Mr. Grossman will also be assuming,the role of Co-Chief ... of its strategic alternatives. , ...
Cached Biology Technology:OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China 2Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets 2XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors 2XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors 3
(Date:4/17/2014)... IPCC meeting painted a stark warning on the possible ... a greenhouse effect 32 times that of carbon dioxide. ... humic substances act as fully regenerable electron acceptors which ... in wetlands instead of being released to the atmosphere. ... disrupted it may enter into a vicious cycle to ...
(Date:4/17/2014)... Branch at Galveston are the first to recommend ... cancer should begin colorectal cancer screening earlier than ... a high incidence of secondary colorectal cancers among ... recommendations that the younger women in this group ... their initial cervical cancer diagnosis instead of waiting ...
(Date:4/17/2014)... a special feature of The Proceedings ... ) published April 29, raises a number of startling ... most of us take for granted. At the end ... around the globe shifted from hunting animals and gathering ... It seems so straightforward and yet the more scientists ...
Breaking Biology News(10 mins):Methane climate change risk suggested by proof of redox cycling of humic substances 2Radiation therapy for cervical cancer increases risk for colorectal cancer 2Genetic study tackles mystery of slow plant domestications 2Genetic study tackles mystery of slow plant domestications 3Genetic study tackles mystery of slow plant domestications 4
... Researchers at Albany Medical College are releasing results of a ... search for new drug targets aimed at preventing or reversing ... stroke. In the March 5 issue of the ... and his colleagues at the college,s Center for Cardiovascular Science ...
... , This release is available in German . ... beewolves, house beneficial bacteria on their cocoons that guarantee ... Institute for Chemical Ecology in Jena teamed up with ... Leibniz Institute for Natural Product Research Hans-Knoell-Institute - ...
... African-Americans age 65 and younger are more than twice ... any region, and people who have a stroke are more ... researchers at the University of Alabama at Birmingham (UAB) School ... for Geographic and Racial Differences in Stroke (REGARDS) study, one ...
Cached Biology News:Preventing or reversing inflammation after heart attack, stroke may require 2-pronged approach 2Beewolves protect their offspring with antibiotics 2Beewolves protect their offspring with antibiotics 3UAB study shows African-Americans have highest stroke rate, southerners more likely to die 2
For the quantitative determination of canine Interferon gamma,(IFN-γ) concentrations in cell culture supernates, serum and,plasma....
Request Info...
Homo sapiens olfactomedin 1, transcript variant 3...
Component of GELase™ Agarose Gel-Digesting Preparation. 1 ml of 50X Buffer is sufficient for replacing the buffer in at least 5 g of gel....
Biology Products: